Crossmark

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

Crossref DOI link: https://doi.org/10.1186/s12885-019-5507-6

Published Online: 2019-04-25

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Connock, Martin

Armoiry, Xavier http://orcid.org/0000-0003-1166-0453
Tsertsvadze, Alexander

Melendez-Torres, G. J.

Royle, Pamela

Andronis, Lazaros

Clarke, Aileen
License Information

Text and Data Mining valid from 2019-04-25
More Information

Article History

Received: 26 January 2018

Accepted: 21 March 2019

First Online: 25 April 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below